AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28381130 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous MSC transplantation
Number of subjects: 24
Study 28381220 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI-targeted biopsies
Number of subjects: 299
Study 28381220 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS-targeted biopsies
Number of subjects: 299
Study 28381220 — intervention group
Group type: COMPARATOR
Intervention: Systematic TRUS-guided biopsies
Number of subjects: 299
Study 28381249 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care alert for cardioprotective medications
Number of subjects: 10
Study 28381395 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile tailored information app for chronic disease self-management
Number of subjects: 0
Study 28381434 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic observation drug susceptibility assay
Number of subjects: 0
Study 28381434 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 28381473 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28381476 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 0
Study 28381476 — intervention group
Group type: COMPARATOR
Intervention: Sedentary time
Number of subjects: 0
Study 28381477 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteropathogen exposure
Number of subjects: 0
Study 28381477 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 0
Study 28382208 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg bid with ≥1 other active antiretroviral (excluding darunavir/ritonavir)
Number of subjects: 211
Study 28382379 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with concurrent and sequential radiotherapy
Number of subjects: 22
Study 28382529 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-detected metabolic system (MS)
Number of subjects: 140
Study 28382529 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts' visual (V) readings
Number of subjects: 140
Study 28382529 — intervention group
Group type: EXPERIMENTAL
Intervention: Software using a log-log transformation (LLT)
Number of subjects: 140
Study 28382566 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-2*IGFBP-7 concentration measured at 12 hours after CPB initiation
Number of subjects: 94
Study 28383392 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir, 17 mg/kg once daily
Number of subjects: 13
Study 28383677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day until disease progression or unacceptable toxicity
Number of subjects: 43
Study 28384199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 7154
Study 28384199 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anticoagulants (DOAC)
Number of subjects: 7154
Study 28384199 — intervention group
Group type: COMPARATOR
Intervention: General practitioners' perception
Number of subjects: 7154
Study 28384285 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 1617
Study 28384285 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 1617
Study 28384285 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin T
Number of subjects: 1617
Study 28384285 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I
Number of subjects: 1617
Study 28384285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 1617
Study 28384285 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall-survival estimates
Number of subjects: 1617
Study 28384285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model
Number of subjects: 1617
Study 28385065 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) 400 mg BID
Number of subjects: 451
Study 28385306 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-68-labeled DOTATATE
Number of subjects: 0
Study 28385306 — intervention group
Group type: COMPARATOR
Intervention: Fluorine-18-labeled fluorodeoxyglucose positron emission tomography
Number of subjects: 0
Study 28385308 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter device implantation
Number of subjects: 15
Study 28386037 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence platform for daily monitoring
Number of subjects: 28
Study 28386037 — intervention group
Group type: COMPARATOR
Intervention: No daily monitoring (control)
Number of subjects: 28
Study 28387632 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-window indocyanine green (ICG) 5 mg/kg injected the day prior to surgery
Number of subjects: 18
Study 28387950 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil cutaneous iontophoresis
Number of subjects: 0
Study 28388260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1132
Study 28388260 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC decline >= 10% to < 15%
Number of subjects: 1132
Study 28388260 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC decline >= 15%
Number of subjects: 1132
Study 28388260 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC decline > 5% to < 10%
Number of subjects: 1132
Study 28388657 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D implantation
Number of subjects: 305
Study 28388956 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of prednisolone for 3 days (days 3-5) along with 1 g of paracetamol per day for 5 days for pain relief.
Number of subjects: 95
Study 28388956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pred-test (20 mg of prednisolone for 3 days)
Number of subjects: 95
Study 28388966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with peptide-pulsed dendritic cells and poly-ICLC
Number of subjects: 12
Study 28389304 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) with add-on therapy
Number of subjects: 171
Study 28389304 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 171
Study 28389391 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 28389391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28389393 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 28389393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28389462 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose araC (HD-araC) used in the second induction cycle
Number of subjects: 204
Study 28389462 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-negative patients (n = 125)
Number of subjects: 204
Study 28389462 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-positive patients (n = 21)
Number of subjects: 204
Study 28389462 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory/relapsed leukemia patients (n = 17)
Number of subjects: 204
Study 28389617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated Spanish language enrollment line
Number of subjects: 1700
Study 28389617 — intervention group
Group type: COMPARATOR
Intervention: Non-Spanish language enrollment
Number of subjects: 1700
Study 28390410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasa® 4000 mg/day in 2 divided doses
Number of subjects: 5695
Study 28390410 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol® 3600 mg/day in 3 divided doses
Number of subjects: 5695
Study 28390410 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of remission maintenance until enrollment 12 to <24 months
Number of subjects: 5695
Study 28390410 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of remission maintenance until enrollment ≥24 months
Number of subjects: 5695
Study 28390437 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication overuse headache (MOH) patients
Number of subjects: 0
Study 28390587 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 39
Study 28390663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal abdominal diameter (SAD) >25 cm
Number of subjects: 635
Study 28390663 — intervention group
Group type: COMPARATOR
Intervention: Waist circumference (WC)
Number of subjects: 635
Study 28391003 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 60
Study 28391235 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative serum albumin drop (ΔAlb) ≥10 g/L on postoperative day 1 (POD 1)
Number of subjects: 138
Study 28391235 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative serum albumin drop (ΔAlb)
Number of subjects: 138
Study 28391409 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews conducted by clinical pharmacists
Number of subjects: 230
Study 28391409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist participation)
Number of subjects: 230
Study 28391409 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medication reviews conducted by clinical pharmacists (after adjustment for heart failure)
Number of subjects: 230
Study 28391409 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc analysis of comprehensive medication reviews
Number of subjects: 230
Study 28391893 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 Index (total n-3 PUFAs)
Number of subjects: 6501
Study 28391893 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 6501
Study 28391893 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 6501
Study 28391893 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA factor score (calculated variable including 6 PUFAs)
Number of subjects: 6501
Study 28391894 — intervention group
Group type: EXPERIMENTAL
Intervention: National genetic cascade screening program for FH (NPFH)
Number of subjects: 9000
Study 28391894 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 9000
Study 28392491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic functional connectivity of the central nucleus of the amygdala (CeA)
Number of subjects: 27
Study 28392491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic functional connectivity of the bed nucleus of the stria terminalis (BNST)
Number of subjects: 27
Study 28393103 — intervention group
Group type: EXPERIMENTAL
Intervention: PICOPREP tailored dosing
Number of subjects: 0
Study 28393103 — intervention group
Group type: COMPARATOR
Intervention: PICOPREP day-before dosing
Number of subjects: 0
Study 28393655 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing side preference (CSP)
Number of subjects: 75
Study 28393673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantheris catheter alone
Number of subjects: 158
Study 28393673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantheris + adjunctive therapy
Number of subjects: 158
Study 28393673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantheris alone
Number of subjects: 158
Study 28393673 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite major adverse events (MAEs)
Number of subjects: 158
Study 28393673 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological analysis of atherectomy specimens
Number of subjects: 158
Study 28394435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) therapy
Number of subjects: 1170
Study 28394435 — intervention group
Group type: COMPARATOR
Intervention: Non-anticoagulant treatment
Number of subjects: 1170
Study 28395663 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 12
Study 28395663 — intervention group
Group type: COMPARATOR
Intervention: Post-cardiac surgery patients (controls)
Number of subjects: 12
Study 28395671 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 41
Study 28395880 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of autologous tumour-infiltrating lymphocytes (TILs)
Number of subjects: 21
Study 28395880 — intervention group
Group type: COMPARATOR
Intervention: Lymphodepleting chemotherapy (intravenous cyclophosphamide [60 mg/kg] daily for 2 days followed by fludarabine [25 mg/m2])
Number of subjects: 21
Study 28395880 — intervention group
Group type: COMPARATOR
Intervention: Lymphodepleting chemotherapy
Number of subjects: 21
Study 28395998 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium histolyticum (CCH) intralesional injection (0.58 mg/injection, up to eight injections)
Number of subjects: 189
Study 28395998 — intervention group
Group type: EXPERIMENTAL
Intervention: CCH treatment of male partners
Number of subjects: 189
Study 28396040 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD)
Number of subjects: 200
Study 28396040 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Management (OMM)
Number of subjects: 200
Study 28396050 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSTs)
Number of subjects: 50
Study 28396050 — intervention group
Group type: EXPERIMENTAL
Intervention: CUSUM test
Number of subjects: 50
Study 28397471 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemia
Number of subjects: 0
Study 28397471 — intervention group
Group type: EXPERIMENTAL
Intervention: High Hcy and MTHFR1298AC + CC genotypes
Number of subjects: 0
Study 28397698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir once daily for 6 weeks
Number of subjects: 26
Study 28398006 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 144
Study 28398341 — intervention group
Group type: EXPERIMENTAL
Intervention: CACNA1C allele A carriers
Number of subjects: 117
Study 28398341 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of CACNA1C allele A
Number of subjects: 117
Study 28398341 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (regardless of CACNA1C rs1006737 A status)
Number of subjects: 117
Study 28399802 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) with rifapentine once weekly for 12 weeks (INH/RPT-3)
Number of subjects: 44149
Study 28399802 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of daily INH (INH-6)
Number of subjects: 44149
Study 28399802 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 months of daily INH (INH-9)
Number of subjects: 44149
Study 28399802 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-4 months daily INH plus rifampicin (INH/RFMP 3-4)
Number of subjects: 44149
Study 28399802 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months daily rifampicin alone (RFMP-4)
Number of subjects: 44149
Study 28399802 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-4 months regimens
Number of subjects: 44149
Study 28399802 — intervention group
Group type: COMPARATOR
Intervention: Active regimens
Number of subjects: 44149
Study 28399802 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter rifamycin-based regimens
Number of subjects: 44149
Study 28399802 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer regimens
Number of subjects: 44149
Study 28399804 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir-containing treatment
Number of subjects: 385
Study 28399804 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-B*57:01 allele testing
Number of subjects: 385
Study 28399804 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-B*57:01 allele prevalence
Number of subjects: 385
Study 28399815 — intervention group
Group type: EXPERIMENTAL
Intervention: cART initiation
Number of subjects: 48
Study 28399830 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) for lung lesion biopsy
Number of subjects: 1000
Study 28399845 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based network promoting smoking cessation services
Number of subjects: 623
Study 28399845 — intervention group
Group type: EXPERIMENTAL
Intervention: Community model of promoting gender-specific smoking cessation services
Number of subjects: 623
Study 28399850 — intervention group
Group type: EXPERIMENTAL
Intervention: General Oral Health Assessment Index (GOHAI)
Number of subjects: 90
Study 28399887 — intervention group
Group type: EXPERIMENTAL
Intervention: Food purchases (HEI-2010 scores)
Number of subjects: 196
Study 28399887 — intervention group
Group type: COMPARATOR
Intervention: 24-h diet recalls (HEI-2010 scores)
Number of subjects: 196
Study 28399887 — intervention group
Group type: EXPERIMENTAL
Intervention: Food purchases (individual nutrient densities)
Number of subjects: 196
Study 28399921 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy + dasatinib (p-Src kinase inhibitor)
Number of subjects: 509
Study 28399921 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 509
Study 28399931 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic CTP (IL1 inhibitor [IL1i] ± GC, IL6 inhibitor [IL6i] ± GC)
Number of subjects: 30
Study 28399931 — intervention group
Group type: COMPARATOR
Intervention: Non-biologic CTP (glucocorticoid [GC] alone, methotrexate [MTX] ± GC)
Number of subjects: 30
Study 28399931 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all CTPs)
Number of subjects: 30
Study 28400193 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells applied in a bioabsorbable matrix
Number of subjects: 12
Study 28400218 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stent grafts
Number of subjects: 103
Study 28400218 — intervention group
Group type: COMPARATOR
Intervention: Above-knee bypass surgery (historical control)
Number of subjects: 103
Study 28400935 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 22
Study 28400935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28401454 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring System (FreeStyle Libre™)
Number of subjects: 224
Study 28401454 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitoring Blood Glucose (SMBG) (FreeStyle Lite™)
Number of subjects: 224
Study 28402487 — intervention group
Group type: EXPERIMENTAL
Intervention: serum klotho (seKL) ≥280 ng/L
Number of subjects: 238
Study 28402487 — intervention group
Group type: COMPARATOR
Intervention: serum klotho (seKL) <280 ng/L
Number of subjects: 238
Study 28403013 — intervention group
Group type: EXPERIMENTAL
Intervention: V2 receptor blockade
Number of subjects: 0
Study 28403013 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in daily water intake
Number of subjects: 0
Study 28403013 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 28403055 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine administered to children <6 months (3 primary doses + booster)
Number of subjects: 300
Study 28403055 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine administered to children 7-11 months (2 primary doses + booster)
Number of subjects: 300
Study 28403055 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine administered to children 12-23 months (2 catch-up doses)
Number of subjects: 300
Study 28403055 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV vaccine
Number of subjects: 300
Study 28403119 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined measurement of soluble ST2 (≥ 500 ng/mL) and amino-terminal pro-B-type natriuretic peptide (≥ 4,500 ng/L) at 12 hours
Number of subjects: 145
Study 28403119 — intervention group
Group type: COMPARATOR
Intervention: CardShock risk score
Number of subjects: 145
Study 28403407 — intervention group
Group type: EXPERIMENTAL
Intervention: THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange), 100% oxygen, 40-70 litres min - 1
Number of subjects: 31
Study 28403407 — intervention group
Group type: COMPARATOR
Intervention: Hyperventilation during pre-oxygenation
Number of subjects: 31
Study 28403822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and chiropractic (A/C) services
Number of subjects: 90
Study 28403822 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about realistic expectations for chronic pain management and therapy options
Number of subjects: 90
Study 28403822 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to A/C care
Number of subjects: 90
Study 28403842 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Number of subjects: 12
Study 28403962 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assistance in surgery for deep infiltrating endometriosis
Number of subjects: 35
Study 28404357 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 34
Study 28404577 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced schedule of therapeutic food distribution
Number of subjects: 0
Study 28404672 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium tuberculosis mutations conferring resistance to second-line antituberculous drugs
Number of subjects: 0
Study 28404690 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine (NBI-98854)
Number of subjects: 0
Study 28404690 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine metabolites
Number of subjects: 0
Study 28405211 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation
Number of subjects: 82
Study 28405211 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding knowledge scores
Number of subjects: 82
Study 28405211 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding belief scores
Number of subjects: 82
Study 28405211 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration
Number of subjects: 82
Study 28405211 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding intent and beliefs
Number of subjects: 82
Study 28405328 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using polyhematoporphyrin
Number of subjects: 88
Study 28405331 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual stiffness colonoscopes
Number of subjects: 475
Study 28405331 — intervention group
Group type: COMPARATOR
Intervention: MEI-guided variable stiffness colonoscopes
Number of subjects: 475
Study 28405343 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based self-help intervention
Number of subjects: 0
Study 28405343 — intervention group
Group type: COMPARATOR
Intervention: KAs with DM
Number of subjects: 0